Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy

EBioMedicine

Volumn 11, Issue , 2016, Pages 43-57

  Zieglmayer, Petra ^a   Focke Tejkl, Margarete ^b   Schmutz, René ^a   Lemell, Patrick ^a   Zieglmayer, René ^a   Weber, Milena ^b   Kiss, Renata ^b   Blatt, Katharina ^c   Valent, Peter ^c   Stolz, Frank ^d   Huber, Hans ^d   Neubauer, Angela ^d   Knoll, Anette ^e   Horak, Friedrich ^a   Henning, Rainer ^d   Valenta, Rudolf ^b  

^a Vienna Challenge Chamber   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d BIOMAY AG   (Austria)

^e SynteractHCR Deutschland GmbH   (Germany)

Author keywords

B cell epitope; Challenge chamber; Grass pollen; Immunotherapy; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; B CELL EPITOPE BASED VACCINE; CORTICOSTEROID; GRASS POLLEN VACCINE; IMMUNOGLOBULIN G; PLACEBO; UNCLASSIFIED DRUG; ALLERGEN; EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN E; PLANT ANTIGEN; VACCINE;

ADULT; ARTICLE; BASOPHIL; BLOOD ANALYSIS; CLINICAL TRIAL (TOPIC); DISEASE ASSESSMENT; DOUBLE BLIND PROCEDURE; FEMALE; FLOW CYTOMETRY; GRASS POLLEN; HUMAN; IMMUNOASSAY; IMMUNOTHERAPY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; POLLEN ALLERGY; PRICK TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN SENSITIZATION; T LYMPHOCYTE ACTIVATION; TOTAL NASAL SYMPTOM SCORE; TOTAL OCULAR SYMPTOM SCORE; ADVERSE EFFECTS; AMINO ACID SEQUENCE; CHEMISTRY; CLINICAL TRIAL; CONTROLLED STUDY; DEGRANULATION; DESENSITIZATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MOLECULAR MODEL; POACEAE; POLLEN; PROCEDURES; PROTEIN CONFORMATION; RANDOMIZED CONTROLLED TRIAL; RHINITIS, ALLERGIC, SEASONAL; SKIN; T LYMPHOCYTE; YOUNG ADULT;

ADULT; ALLERGENS; AMINO ACID SEQUENCE; ANTIGENS, PLANT; BASOPHILS; CELL DEGRANULATION; DESENSITIZATION, IMMUNOLOGIC; EPITOPES, B-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MODELS, MOLECULAR; POACEAE; POLLEN; PROTEIN CONFORMATION; RECOMBINANT FUSION PROTEINS; RHINITIS, ALLERGIC, SEASONAL; SKIN; T-LYMPHOCYTES; VACCINES; YOUNG ADULT;

EID: 84994807376     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.08.022     Document Type: Article

References (49)

1. Banerjee, S., Weber, M., Blatt, K., et al. Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine. J. Immunol. 192 (2014), 4867–4875.
2. Campana, R., Moritz, K., Marth, K., et al. Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. J. Allergy Clin. Immunol. 137:2 (2015), 601–609.
3. Casset, A., Mari, A., Purohit, A., et al. Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts. Int. Arch. Allergy Immunol. 159:3 (2012), 253–262.
4. Cornelius, C., Schöneweis, K., Georgi, F., Weber, M., Niederberger, V., Zieglmayer, P., Niespodziana, K., Trauner, M., Hofer, H., Urban, S., Valenta, R., Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. EBioMedicine. 11 (2016), 58–67.
5. Creticos, P.S., Schroeder, J.T., Hamilton, R.G., et al. Immune tolerance network group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355 (2006), 445–455.
6. Devillier, P., Chassany, O., Vicaut, E., et al. The minimally important difference in the Rhinoconjunctivitis Total Symptom Score in grass-pollen-induced allergic rhinoconjunctivitis. Allergy 69:12 (2014), 1689–1695.
7. Drachenberg, K.J., Wheeler, A.W., Stuebner, P., Horak, F., A well tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56 (2001), 498–505.
8. Durham, S.R., Walker, S.M., Varga, E.M., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341 (1999), 468–475.
9. Durham, S.R., Yang, W.H., Pedersen, M.R., et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117 (2006), 802–809.
10. Focke, M., Mahler, V., Ball, T., et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J. 15:11 (2001), 2042–2044.
11. Focke, M., Marth, K., Flicker, S., Valenta, R., Heterogeneity of commercial timothy grass pollen extracts. Clin. Exp. Allergy 38 (2008), 1400–1408.
12. Focke, M., Swoboda, I., Marth, K., Valenta, R., Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin. Exp. Allergy 40 (2010), 385–389.
13. Focke-Tejkl, M., Campana, R., Reininger, R., et al. Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5. J. Allergy Clin. Immunol. 133:3 (2014), 836–845.
14. Focke-Tejkl, M., Weber, M., Niespodziana, K., et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J. Allergy Clin. Immunol., 135, 2015, 1207.
15. Gadermaier, E., Flicker, S., Aberer, W., et al. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide. Int. Arch. Allergy Immunol., 151, 2010 (17-2).
16. Gadermaier, E., Staikuniene, J., Scheiblhofer, S., et al. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation. Allergy 66 (2011), 1174–1182.
17. Gallerano, D., Ndlovu, P., Makupe, I., et al. Comparison of the specificities of IgG, IgG-Subclass, IgA and IgM reactivities in African and European HIV-infected individuals with an HIV-1 Clade C proteome-based array. PLoS ONE, 10, 2015, e0117204.
18. Gerlich, W.H., Glebe, D., Development of an Allergy Immunotherapy Leads to a New Type of Hepatitis B Vaccine. EBioMedicine. 11 (2016), 5–6.
19. Hankin, C.S., Cox, L., Allergy immunotherapy: what is the evidence for cost saving?. Curr. Opin. Allergy Clin. Immunol. 14 (2014), 363–370.
20. Hatzler, L., Panetta, V., Lau, S., et al. Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J. Allergy Clin. Immunol. 130:4 (2012), 894–901.
21. Hauswirth, A.W., Natter, S., Ghannadan, M., et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J. Allergy Clin. Immunol. 110 (2002), 102–109.
22. Horak, F., Zieglmayer, P., Zieglmayer, R., et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J. Allergy Clin. Immunol. 124 (2009), 471–477.
23. Horak, F., Zieglmayer, P., Zieglmayer, R., et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm. Res. 59 (2010), 391–398.
24. Horn, M., Vollandt, R., Sample sizes for comparisons of k treatments with a control based on different definitions on power. Biom. J. 40 (1998), 589–612.
25. Jacobsen, L., Niggemann, B., Dreborg, S., et al. (The PAT investigator group). Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62 (2007), 943–948.
26. Kiel, M.A., Röder, E., Gerth van Wijk, R., et al. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J. Allergy Clin. Immunol. 132 (2013), 353–360.
27. Kleine-Tebbe, J., Fuchs, T., Klimek, L., et al. Allergen immunotherapy — a position paper of the German society for allergology and clinical immunology. Pneumologie 55 (2001), 438–444.
28. Larché, M., Akdis, C.A., Valenta, R., Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol. 6 (2006), 761–771.
29. Linhart, B., Hartl, A., Jahn-Schmid, B., et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J. Allergy Clin. Immunol. 115:5 (2005), 1010–1016.
30. Linhart, B., Narayanan, M., Focke-Tejkl, M., et al. Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. Clin. Exp. Allergy 44 (2014), 278–287.
31. Lupinek, C., Wollmann, E., Baar, A., et al. Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip. Methods 66 (2014), 106–119.
32. Lupinek, C., Wollmann, E., Valenta, R., Monitoring allergen immunotherapy effects by microarray. Curr. Treat. Options Allergy 3 (2016), 189–203.
33. Marth, K., Breyer, I., Focke-Tejkl, M., et al. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J. Immunol. 190 (2013), 3068–3078.
34. Mothes, N., Heinzkill, M., Drachenberg, K.J., et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy 33 (2003), 1198–1208.
35. Niederberger, V., Horak, F., Vrtala, S., et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl. Acad. Sci. U. S. A. 101:Suppl. 2 (2004), 14677–14682.
36. Niederberger, V., Marth, K., Eckl-Dorna, J., et al. Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients. J. Allergy Clin. Immunol. 136 (2015), 1101–1103.
37. Niespodziana, K., Focke-Tejkl, M., Linhart, B., et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J. Allergy Clin. Immunol., 127, 2011 (1562-70.e6).
38. Pfaar, O., Demoly, P., van Wijk R, G., et al. European Academy of Allergy and Clinical Immunology. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 69 (2014), 854–867.
39. Purohit, A., Niederberger, V., Kronqvist, M., et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin. Exp. Allergy 38 (2008), 1514–1525.
40. Rendi-Wagner, P., Shouval, D., Genton, B., et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 24 (2006), 2781–2789.
41. Schmid, J.M., Würtzen, P.A., Dahl, R., Hoffmann, H.J., Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract. J. Allergy Clin. Immunol. 137:2 (2016), 562–570.
42. Spertini, F., Perrin, Y., Audran, R., et al. Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides. J. Allergy Clin. Immunol. 34 (2014), 239–240.
43. Suphioglu, C., Singh, M.B., Taylor, P., et al. Mechanism of grass-pollen-induced asthma. Lancet 7 (1992), 569–572.
44. Tamhane, A.C., Hochberg, Y., Dunnett, C.W., Multiple test procedures for dose finding. Biometrics 52 (1996), 21–37.
45. Valenta, R., Ferreira, F., Focke-Tejkl, M., et al. From allergen genes to allergy vaccines. Annu. Rev. Immunol. 28 (2010), 211–214.
46. Valenta, R., Campana, R., Marth, K., van Hage, M., Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J. Intern. Med. 272 (2012), 144–157.
47. van Neerven, R.J., Wikborg, T., Lund, G., et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4 + T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol. 163:5 (1999), 2944–2952.
48. Winther, L., Arnved, J., Malling, H.J., et al. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin. Exp. Allergy 36 (2006), 254–260.
49. Wollmann, E., Lupinek, C., Kundi, M., et al. Reduction in allergen-specific IgE binding as measured by microarray: a possible surrogate marker for effects of specific immunotherapy. J. Allergy Clin. Immunol. 136 (2015), 806–809.